Kamada Ltd. (KMDA) Given Average Rating of “Strong Buy” by Analysts
Shares of Kamada Ltd. (NASDAQ:KMDA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $8.50 for the company and are predicting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Kamada an industry rank of 110 out of 265 based on the ratings given to its competitors.
KMDA has been the subject of several recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 price objective (down from $9.00) on shares of Kamada in a report on Wednesday, August 2nd. TheStreet downgraded shares of Kamada from a “c-” rating to a “d+” rating in a report on Tuesday, August 1st. Zacks Investment Research downgraded shares of Kamada from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a report on Friday, September 1st.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in shares of Kamada during the 3rd quarter worth $112,000. Worth Venture Partners LLC bought a new stake in shares of Kamada during the 3rd quarter worth $246,000. Edmond DE Rothschild Holding S.A. boosted its holdings in shares of Kamada by 10.5% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after buying an additional 4,000 shares during the period. Navellier & Associates Inc bought a new stake in shares of Kamada during the 2nd quarter worth $303,000. Finally, Analyst IMS Investment Management Services Ltd. boosted its holdings in shares of Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after buying an additional 50,000 shares during the period. 6.94% of the stock is owned by institutional investors and hedge funds.
Kamada (KMDA) traded up $0.10 during midday trading on Monday, hitting $4.75. 2,600 shares of the company traded hands, compared to its average volume of 71,219. The company has a quick ratio of 2.73, a current ratio of 3.71 and a debt-to-equity ratio of 0.02. Kamada has a fifty-two week low of $3.75 and a fifty-two week high of $8.61.
ILLEGAL ACTIVITY NOTICE: “Kamada Ltd. (KMDA) Given Average Rating of “Strong Buy” by Analysts” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/kamada-ltd-kmda-given-average-rating-of-strong-buy-by-analysts/1729248.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.